Q2 INTERIM REPORT APRIL - JUNE 2022
READ MORE
Mentice acquires Ankyras solutions from Galgo Medical SL
READ MORE

Nomination committee has been appointed for Mentice AB (publ) Annual General Meeting 2020

Wednesday, November 27, 2019

Mentice AB (STO: MNTC), a world leader in simulation solutions for endovascular therapies, announces that the nomination committee for the company’s Annual General Meeting 2020 has been appointed.

At the Annual General Meeting held on 17 April 2019, it was resolved to adopt instructions and rules of procedure for the nomination committee to which the nomination committee shall consist of the chairman of the board of directors and three ordinary members representing the three largest shareholders by the end of third quarter each year.

The following members have been appointed to Mentice nomination committee for the 2020 Annual General Meeting:

Karin Howell as largest shareholder

Sophie Hagströmer, representing Bure Equity

Magnus Hardmeier, representing Priveq Investment

Lawrence D Howell, Chairman of the Board

The nomination committee accordingly represents approximately 51% of the total number of shares and votes.

The Nomination Committee shall prepare and present proposals for resolution by the Annual General Meeting regarding:

  • Election of a Chairman of the meeting
  • Decision on the number of Board members
  • Decision on remuneration to the Board members and to the Auditor
  • Election of Board members and Chairman of the Board
  • If the Nomination Committee deems necessary, propose a new process of appointing a new Nomination Committee.

The Annual General Meeting will take place in Gothenburg on May 27, 2020. Shareholders who have proposals for the Annual General Meeting or comments on the work of the nomination committee are asked to submit these to the nomination committee by email to info@mentice.com, or by letter to: Mentice AB (publ), the nomination committee, Odinsgatan 10, 411 03 Gothenburg. In order for the nomination committee to process the received proposals with sufficient care, proposals must be submitted no later than April 10, 2020.

For further information, please contact:
Göran Malmberg, CEO, Mentice
Email: 
goran.malmberg@mentice.com

US mobile. +1 (312) 860 5610

Sweden mobile +46 (0) 703 09 22 22

Market place: Nasdaq First North Premier, Stockholm | Ticker symbol: MNTC
Certified Adviser: FNCA Sweden AB, tel +46 8 528 00 399 email info@fnca.se

>20 years of innovation in medical simulation | more information at www.mentice.com
Mentice is the world leader in software and hardware simulation solutions for endovascular therapies. Our solutions help healthcare professionals acquire, retain, and enhance their procedural skills driving improved productivity and outcomes. Mentice solutions are scientifically validated and have been specifically developed for healthcare providers and the medical device industry. Neurovascular, cardiovascular and peripheral interventions are just some of the clinical areas covered by our solutions.

DELÅRSRAPPORT Q2 APRIL - JUNI 2022
LÄS MER
Mentice förvärvar Ankyras från det spanska företaget Galgo Medical S.L.
LÄS MER

Nomination committee has been appointed for Mentice AB (publ) Annual General Meeting 2020

Wednesday, November 27, 2019

Mentice AB (STO: MNTC), a world leader in simulation solutions for endovascular therapies, announces that the nomination committee for the company’s Annual General Meeting 2020 has been appointed.

At the Annual General Meeting held on 17 April 2019, it was resolved to adopt instructions and rules of procedure for the nomination committee to which the nomination committee shall consist of the chairman of the board of directors and three ordinary members representing the three largest shareholders by the end of third quarter each year.

The following members have been appointed to Mentice nomination committee for the 2020 Annual General Meeting:

Karin Howell as largest shareholder

Sophie Hagströmer, representing Bure Equity

Magnus Hardmeier, representing Priveq Investment

Lawrence D Howell, Chairman of the Board

The nomination committee accordingly represents approximately 51% of the total number of shares and votes.

The Nomination Committee shall prepare and present proposals for resolution by the Annual General Meeting regarding:

  • Election of a Chairman of the meeting
  • Decision on the number of Board members
  • Decision on remuneration to the Board members and to the Auditor
  • Election of Board members and Chairman of the Board
  • If the Nomination Committee deems necessary, propose a new process of appointing a new Nomination Committee.

The Annual General Meeting will take place in Gothenburg on May 27, 2020. Shareholders who have proposals for the Annual General Meeting or comments on the work of the nomination committee are asked to submit these to the nomination committee by email to info@mentice.com, or by letter to: Mentice AB (publ), the nomination committee, Odinsgatan 10, 411 03 Gothenburg. In order for the nomination committee to process the received proposals with sufficient care, proposals must be submitted no later than April 10, 2020.

For further information, please contact:
Göran Malmberg, CEO, Mentice
Email: 
goran.malmberg@mentice.com

US mobile. +1 (312) 860 5610

Sweden mobile +46 (0) 703 09 22 22

Market place: Nasdaq First North Premier, Stockholm | Ticker symbol: MNTC
Certified Adviser: FNCA Sweden AB, tel +46 8 528 00 399 email info@fnca.se

>20 years of innovation in medical simulation | more information at www.mentice.com
Mentice is the world leader in software and hardware simulation solutions for endovascular therapies. Our solutions help healthcare professionals acquire, retain, and enhance their procedural skills driving improved productivity and outcomes. Mentice solutions are scientifically validated and have been specifically developed for healthcare providers and the medical device industry. Neurovascular, cardiovascular and peripheral interventions are just some of the clinical areas covered by our solutions.